VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFN? for the Treatment of Chronic Hepatitis B
Stock Information for VBI Vaccines Inc.
Loading
Please wait while we load your information from QuoteMedia.